Educational Symposium

Autosomal Dominant Polycystic Kidney Disease: Approach to Patient Assessment and Management

November 08, 2019 | 12:45 PM - 01:45 PM

Location: Liberty Ballroom, Marriott Marquis

Session Description

The past decade has seen impressive advances in the understanding of the pathogenesis and natural history of ADPKD; the identification of genetic, imaging, and biochemical biomarkers of disease progression; and the approval of the first drug for its treatment.

This symposium provides nephrologists with practical information on evaluating individual patient risk for rapid disease progression. It describes how to approach the selection of patients for drug therapy and options for enrolling patients in ongoing trials of novel therapies. The importance of considering the priorities of patients and family members is highlighted.

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Consider the patient perspective in the management of ADPKD
  • Discuss options for stratifying the risk of disease progression in ADPKD
  • Describe current therapeutic options for ADPKD and emerging therapies

Learning Pathway(s)

  • Genetic Diseases of the Kidneys


  • Reem Mustafa, MD, PhD, MPH, FASN


  • Introduction: Brief Review of Patient Priorities in ADPKD
    12:45 PM - 12:55 PM
    Reem Mustafa, MD, PhD, MPH, FASN
  • Who Is at Risk for Rapid Progression in ADPKD?
    12:55 PM - 01:15 PM
    Vicente E. Torres, MD, PhD
  • Clinical Care and Clinical Trials for Patients with ADPKD in a New Therapeutic Era
    01:15 PM - 01:35 PM
    Gopi Rangan, MBBS, PhD
  • Questions and Answers
    01:35 PM - 01:45 PM